Diagnosis and Treatment of Acute Hepatitis C Virus Infection

Infectious Disease Clinics of North America

Volumn 26, Issue 4, 2012, Pages 995-1010

  Boesecke, Christoph ^a   Wedemeyer, Heiner ^b   Rockstroh, Jürgen Kurt ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute hepatitis C; Coinfection; Hepatitis C virus; HIV; Injection drug use; Monoinfection

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ACUTE HEPATITIS C; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; MORBIDITY; NEEDLESTICK INJURY; NONHUMAN; PHYLOGENY; PREVALENCE; REVIEW; SEROCONVERSION; SEXUAL INTERCOURSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRAL CLEARANCE; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 84867665278     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.08.011     Document Type: Review

References (125)

1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011, 55(2):245-264.
2. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
3. Robotin M.C., Copland J., Tallis G., et al. Surveillance for newly acquired hepatitis C in Australia. J Gastroenterol Hepatol 2004, 19:283-288.
4. Wu H.X., Wu J., Wong T., et al. Enhanced surveillance of newly acquired hepatitis C virus infection in Canada, 1998 to 2004. Scand J Infect Dis 2006, 38:482-489.
5. Rantala M., van de Laar M.J. Surveillance and epidemiology of hepatitis B and C in Europe-a review. Euro Surveill 2008, 13:18880.
6. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
7. Mele A., Tosti M.E., Marzolini A., et al. Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group. J Viral Hepat 2000, 7:30-35.
8. Patrick D.M., Tyndall M.W., Cornelisse P.G., et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001, 165:889-895.
9. Maher L., et al. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101:1499-1508.
10. Roy E., Alary M., Morissette C., et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007, 18:23-27.
11. Roy E., Boudreau J.F., Boivin J.F. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience. Drug Alcohol Depend 2009, 102:158-161.
12. Grebely J., Prins M., Hellard M., et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012, 12(5):408-414.
13. Lacombe K., Rockstroh J.K. HIV and viral hepatitis co-infections: advances and challenges. Gut 2012, 61(Suppl 1):i47-i58.
14. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
15. Daniels D., Grytdal S., Wasley A. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 2009, 58:1-27.
16. Vogel M., Deterding K., Wiegand J., et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals: experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009, 49:317-319. [author reply: 9].
17. Deterding K., Wiegand J., Grüner N., et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009, 47(6):531-540.
18. Marincovich B., Castilla J., del Romero J., et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003, 79:160-162.
19. Vandelli C., Renzo F., Romano L., et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004, 99:855-859.
20. van de Laar T.J., Paxton W.A., Zorgdrager F., et al. Sexual transmission of hepatitis C virus in human immunodeficiency virus-negative men who have sex with men: a series of case reports. Sex Transm Dis 2011, 38(2):102-104.
21. Nguyen O., Sheppeard V., Douglas M.W., et al. Acute hepatitis C infection with evidence of heterosexual transmission. J Clin Virol 2010, 49:65-68.
22. Carey J.W., Mejia R., Bingham T., et al. Drug use, high-risk sex behaviors, and increased risk for recent HIV infection among men who have sex with men in Chicago and Los Angeles. AIDS Behav 2009, 13:1084-1096.
23. Thiede H., Jenkins R.A., Carey J.W., et al. Determinants of recent HIV infection among Seattle-area men who have sex with men. Am J Public Health 2009, 99(Suppl 1):S157-S164.
24. Luetkemeyer A., Hare C.B., Stansell J., et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006, 41:31-36.
25. Cox A.L., Page K., Bruneau J., et al. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology 2009, 136(1):26-31.
26. Giraudon I., Ruf M., Maguire H., et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak?. Sex Transm Infect 2008, 84:111-115.
27. Ruf M., Cohuet S., Maguire H., SNAHC Steering Group, et al. Setting up an enhanced surveillance of newly acquired hepatitis C infection in men who have sex with men: a pilot in London and South East region of England. Euro Surveill 2008, 13(47). pii.19042.
28. Gambotti L., Batisse D., Colin-de-Verdiere N., et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005, 10:115-117.
29. Morin T., Pariente A., Lahmek P., et al. Favorable outcome of acute occupational hepatitis C in healthcare workers: a multicenter French study on 23 cases. Eur J Gastroenterol Hepatol 2011, 23(6):515-520.
30. Urbanus A.T., van de Laar T.J., Stolte I.G., et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009, 23:F1-7.
31. Rauch A., Rickenbach M., Weber R., et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005, 41:395-402.
32. Gallotta G, Gali L, De Bona A, et al. Acute hepatitis C virus in HIV co-infected men who have sex with men: Milan, 1996-2007. Presented at the 4th International HIV and Hepatitis Co-infection. Madrid, June 19-21, 2008.
33. Matthews G., Hellard M., Haber P., et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009, 48:650-658.
34. Sherman K.E., Rouster S.D., Horn P.S. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis 2002, 35(4):482-487.
35. Soriano V., Mocroft A., Rockstroh J., et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198:1337-1344.
36. Matthews G.V., Pham S.T., Hellard M., et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2011, 52(6):803-811.
37. Arends J.E., Lambers F.A., van der Meer J.T., et al. Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management. Neth J Med 2011, 69(1):43-49.
38. Neukam K., Nattermann J., Rallón N., et al. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. HIV Med 2011, 12(8):487-493.
39. Bottieau E., Apers L., Van Esbroeck M., et al. Hepatitis C virus infection in HIV-infected men who have sex with men: sustained rising incidence in Antwerp, Belgium, 2001-2009. Euro Surveill 2010, 15(39):19673.
40. Barfod T.S., Omland L.H., Katzenstein T.L. Incidence and characteristics of sexually transmitted acute hepatitis C virus infection among HIV-positive men who have sex with men in Copenhagen, Denmark during four years (2006-2009): a retrospective cohort study. Scand J Infect Dis 2011, 43(2):145-148.
41. Dionne-Odom J., Osborn M.K., Radziewicz H., et al. Acute hepatitis C and HIV coinfection. Lancet Infect Dis 2009, 9(12):775-783.
42. Remis RA. Study to Characterize the Epidemiology of Hepatitis C Infection in Canada. 2002. Final Report. Public Health Agency of Canada. Available at: Accessed May 20, 2012. http://www.phac-aspc.gc.ca/hepc/pubs/hepc2002/index-eng.php.
43. Lebanese Republic, Ministry of Public Health. UNGASS Country Progress Report Lebanon March 2010. Available at: Accessed May 20, 2012. http://www.unaids.org/en/dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/lebanon_2010_country_progress_report_en.pdf.
44. Boesecke C, Stellbrink HJ, Mauss S, et al. Does Baseline HCV Genotype Have an Impact upon Treatment Outcome of Acute HCV Infection in HIV Co-Infected Individuals? Presented at the 18th Conference on Retroviruses and Opportunistic Infections. Boston, February 27-March 2, 2011.
45. Sun H.Y., Chang S.Y., Yang T.Y., et al. Recent hepatitis C virus infection in HIV-positive patients in Taiwan: incissdence and risk factors. J Clin Microbiol 2012, 50(3):781-787.
46. Lee H.C., Ko N.Y., Lee N.Y., et al. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000-2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008, 107(5):404-411.
47. Larsen C, Alric L, Auperin I, et al. Acute hepatitis C in HIV-infected men who have sex with men in France in 2006 and 2007. Presented at the 58th Annual Meeting of the American Association for the Study of the Liver. Boston, November 2-6, 2007.
48. Clausen L.N., Weis N., Astvad K., et al. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J Viral Hepat 2011, 18(4):e66-e74.
49. van der Helm J.J., Prins M., Del Amo J., et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011, 25(8):1083-1091.
50. Fierer D, Fishman S, Uriel A, et al. Characterization of an outbreak of acute HCV infection in HIV-infected men in New York city. Presented at the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8-11, 2009.
51. Hung C.C., Chen M.Y., Hsieh S.M., et al. Impact of chronic hepatitis C infection on outcomes of patients with an advanced stage of HIV-1 infection in an area of low prevalence of co-infection. Int J STD AIDS 2005, 16(1):42-48.
52. Schmidt A.J., Rockstroh J.K., Vogel M., et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany-a case-control study. PLoS One 2011, 6(3):e17781.
53. van de Laar T., Pybus O., Bruisten S., et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009, 136:1609-1617.
54. Vogel M., van de Laar T., Kupfer B., et al. Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany. Liver Int 2010, 30(8):1169-1172.
55. McGovern B.H., Brich C.E., Bowen M.J., et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009, 24:1051-1060.
56. Thomson E.C., Nastouli E., Main J., et al. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009, 23:89-93.
57. The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS 2011, 25(4):399-409.
58. Kubitschke A., Bahr M.J., Aslan N., et al. Induction of hepatitis C virus (HCV)-specific T cells by needle stick injury in the absence of HCV-viraemia. Eur J Clin Invest 2007, 37(1):54-64.
59. Stellbrink H.J., Schewe C.K., Vogel M., et al. Increasing numbers of acute hepatitis C infections in HIV-infected MSM and high reinfection rates following SVR. J Int AIDS Soc 2010, 13(Suppl 4):P200.
60. Lambers F., Prins M., Thomas X., et al. High incidence rate of HCV reinfection after treatment of acute HCV infection in HIV-infected MSM in Amsterdam. AIDS 2011, 25(17):F21-F27.
61. Ingiliz P, Krznaric I, Hoffmann C, et al. Prior HCV Infection Does Not Protect from Sexually Transmitted HCV Reinfection in HIV+ MSM. Presented at the 19th Conference on Retroviruses and Opportunistic Infections. Seattle, March 5-8, 2012.
62. Micallef J.M., Kaldor J.M., Dore G.J. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006, 13:34-41.
63. Wiese M., Berr F., Lafrenz M., et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000, 32(1):91-96.
64. Grebely J., Petoumenos K., Hellard M., ATAHC Study Group, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010, 52(4):1216-1224.
65. Jones L, Uriel A, Kaplan D, et al. Natural history and treatment outcome of acute hepatitis C with and without HIV co-infection in a North American cohort. Peesented at the AASLD 2008 Meeting. San Francisco, California. October 31-November 1, 2008.
66. Thomson E., Fleming V.M., Main J., et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2011, 60(6):837-845.
67. Thomas D.L., Astemborski J., Rai R.M., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
68. Grebely J., Matthews G.V., Petoumenos K., et al. Spontaneous clearance and the beneficial impact of treatment on clearance during recent hepatitis C virus infection. J Viral Hepat 2009, 17:896.
69. Page K., Hahn J.A., Evans J., et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009, 200:1216-1226.
70. McGovern B.H., Wurcel A., Kim A.Y., et al. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis 2006, 42:1663-1670.
71. Wang C.C., Krantz E., Klarquist J., et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 2007, 196:1474-1482.
72. Diepolder H.M. New insights into the immunopathogenesis of chronic hepatitis C. Antiviral Res 2009, 82:103-109.
73. Post J., Ratnarajah S., Lloyd A.R. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009, 66:733-756.
74. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009, 119:1745-1754.
75. Bowen D.G., Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436:946-952.
76. Takaki A., Wiese M., Maertens G., et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000, 6:578-582.
77. Ray S.C., Wang Y.M., Laeyendecker O., et al. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 1999, 73:2938-2946.
78. Farci P., Shimoda A., Coiana A., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
79. Harfouch S., Guiguet M., Valantin M.A., et al. Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection. J Hepatol 2012, 56(6):1259-1268.
80. Schlaphoff V., Lunemann S., Suneetha P.V., et al. Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog 2011, 7(5):e1002045.
81. Schulze Zur Wiesch J., Ciuffreda D., Lewis-Ximenez L., et al. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012, 209(1):61-75.
82. Khakoo S.I., Thio C.L., Martin M.P., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004, 305(5685):872-874.
83. Stegmann K.A., Björkström N.K., Ciesek S., et al. Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis 2012, 205(9):1351-1362.
84. Santantonio T., Wiegand J., Gerlach J.T. Acute hepatitis C: current status and remaining challenges. J Hepatol 2008, 49(4):625-633.
85. Gilleece Y.C., Browne R.E., Asboe D., et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005, 40:41-46.
86. Harris H.E., Eldridge K.P., Harbour S., et al. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?. J Viral Hepat 2007, 14:213-220.
87. Thomas D.L., Thio C.L., Martin M.P., et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
88. Rauch A., Kutalik Z., Descombes P., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. e1331-7.
89. Ge D., Fellay J., Thompson A.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
90. Beinhardt S., Aberle J.H., Strasser M., et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology 2012, 142(1):78-85.e2.
91. Tillmann H.L., Thompson A.J., Patel K., et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010, 139:1586-1592.
92. Rao H.Y., Sun D.G., Jiang D., et al. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J Viral Hepat 2012, 19(3):173-181.
93. Deuffic-Burban S., Castel H., Wiegand J., et al. Immediate versus delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. J Hepatol 2012, 57(2):260-266.
94. Fierer D.S., Uriel A.J., Carriero D.C., et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008, 198(5):683-686.
95. Vogel M., Page E., Boesecke C., et al. Liver fibrosis progression after acute HCV infection (AHC) in HIV-positive individuals. Clin Infect Dis 2012, 54(4):556-559.
96. Wiegand J., Buggisch P., Boecher W., et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006, 43:250-256.
97. Deterding K, Gruner NH, Buggisch P, et al. Early versus delayed treatment of acute hepatitis C: the German HEP-NET Acute HCV-III study - a randomized controlled trial. Presented at the 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012). Barcelona, Spain, April 18-22, 2012.
98. Dintsios C.M., Haverkamp A., Wiegand J., et al. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany. Eur J Gastroenterol Hepatol 2010, 22(3):278-288.
99. Vogel M., Boesecke C., Rockstroh J.K. Acute hepatitis C infection in HIV-positive patients. Curr Opin Infect Dis 2011, 24(1):1-6.
100. Vogel M, Page E, Matthews G, et al. Use of week 4 HCV RNA after acute HCV infection to predict chronic HCV infection. Presented at the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, California, February 16-19, 2010.
101. Dore G.J., Hellard M., Matthews G.V., et al. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 2010, 138(1):123-135.e1-2.
102. Jaeckel E., Cornberg M., Wedemeyer H., et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001, 345:1452-1457.
103. Nomura H., Sou S., Tanimoto H., et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004, 39:1213-1219.
104. Santantonio T., Fasano M., Sinisi E., et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005, 42:329-333.
105. Gerlach J.T., Diepolder H.M., Zachoval R., et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003, 125:80-88.
106. Vogel M., Nattermann J., Baumgarten A., et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006, 11:1097-1101.
107. Schnuriger A., Dominguez S., Guiguet M., ANRS HC EP21 study group, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009, 23:2079-2089.
108. Dominguez S., Ghosn J., Valantin M.A., et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006, 20:1157-1161.
109. Kruk A. Efficacy of acute HCV treatment with peg-interferon alfa-2b and ribavirin in HIV-infected patients. Presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 24-27, 2005.
110. Serpaggi J., Chaix M.L., Batisse D., et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006, 20:233-240.
111. Piroth L., Larsen C., Binquet C., Steering Committee of the HEPAIG Study, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology 2010, 52(6):1915-1921.
112. Nunez M., Miralles C., Berdun M.A., et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007, 23:972-982.
113. Vogel M., Ahlenstiel G., Hintsche B., et al. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals. Eur J Med Res 2010, 15:102-111.
114. Matthews G, Grebely J, Hellard M, et al. Differences in early virological decline in individuals treated within the Australian Trial in Acute HCV suggest a potential benefit for the use of ribavirin. Presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, Austria, April 14-18, 2010.
115. Grebely J., Hellard M., Applegate T., et al. Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS 2012, 26(13):1653-1661.
116. Nattermann J., Vogel M., Nischalke H.D., et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011, 203(5):595-601.
117. Grebely J., Matthews G.V., Dore G.J. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011, 8(5):265-274.
118. Calleri G., Cariti G., Gaiottino F., et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007, 14:116-121.
119. Vogel M., Dominguez S., Bhagani S., et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010, 15:267-279.
120. Lambers F., Brinkman K., Schinkel J., et al. Treatment of acute hepatitis C virus infection in HIV-infected MSM: the effect of treatment duration. AIDS 2011, 25(10):1333-1336.
121. Matthews G.V., Dore G.J. Optimal duration of treatment for acute hepatitis C in human immunodeficiency virus-positive individuals?. Hepatology 2011, 53(3):1055-1056. [author reply: 1056-7].
122. Dorward J., Garrett N., Scott D., et al. Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. J Clin Virol 2011, 52(4):367-369.
123. Carlsson T., Quist A., Weiland O., et al. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. J Med Virol 2008, 80(5):803-807.
124. Wedemeyer H., Cornberg M., Wiegand J., et al. Treatment duration in acute hepatitis C: the issue is not solved yet. Hepatology 2006, 44:1051-1052.
125. Boesecke C., Rockstroh J.K. Treatment of acute hepatitis C infection in HIV-infected patients. Curr Opin HIV AIDS 2011, 6(4):278-284.